|
|
| | β-Aminoarteether maleate Basic information |
| | β-Aminoarteether maleate Chemical Properties |
| | β-Aminoarteether maleate Usage And Synthesis |
| Uses | β-Aminoarteether maleate (SM934) is an Artemisinin derivative with orally active. β-Aminoarteether maleate can be used for inflammation and autoimmune disease research, such as lupus diseases[1]. | | in vivo | β-Aminoarteether (SM934; 1-10 mg/kg; oral administration; daliy; for 3 months) treatment significantly delays the progression of glomerulonephritis and increases the survival rate of NZB/W F1 mice. β-Aminoarteether treatment promots the IL-10 production of macrophages from NZB/W F1 mice[1]. | Animal Model: | Female NZB/W F1 mice (Six and half months old)[1] | | Dosage: | 1 mg/kg, 3 mg/kg, and 10 mg/kg | | Administration: | Oral administration; daliy; for 3 months | | Result: | Significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice. |
| | References | [1] Li-Fei Hou, et al. SM934 treated lupus-prone NZB × NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development. PLoS One. 2012;7(2):e32424. DOI:10.1371/journal.pone.0032424
[2] Yang FM, Fan D, Yang XQ, et al. The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling. Acta Pharmacol Sin. 2021;42(4):593-603. DOI:10.1038/s41401-020-0484-5 |
| | β-Aminoarteether maleate Preparation Products And Raw materials |
|